J&J/Merck's Mylanta AR covered under Pepcid AC NDA.
This article was originally published in The Tan Sheet
Executive Summary
MYLANTA AR COVERED UNDER PEPCID AC NDA, according to J&J/Merck. The company was not required to submit a new NDA for the Mylanta acid blocker, which contains 10 mg famotidine -- the same active ingredient at the same dose as J&J/Merck's Pepcid AC. The company launched Pepcid AC, which was first to market in the acid blocker category and is the top-selling H2 antagonist, in June 1996.
You may also be interested in...
Bayer Aleve sNDA Approval Provides Midol Brand 12-Hour Relief Indication
Bayer's Midol menstrual pain franchise soon could include SKUs with three different primary OTC pain relief ingredients
Bayer Aleve sNDA Approval Provides Midol Brand 12-Hour Relief Indication
Bayer's Midol menstrual pain franchise soon could include SKUs with three different primary OTC pain relief ingredients
Bayer Aleve sNDA Approval Provides Midol Brand 12-Hour Relief Indication
Bayer's Midol menstrual pain franchise soon could include SKUs with three different primary OTC pain relief ingredients